The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. READ MORE

Author Insights

While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.

READ MORE

CAR-T

The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.

READ MORE

A recent study reported an ORR of 71% in patients with CLL treated with anti-CD19 CAR-T cell therapy after prior treatment failure.

READ MORE

Standardized CD19-specific CAR-modified T cells along with chemotherapy can more effectively guide treatment and improve response in patients with relapsed and refractory B cell non-Hodgkin's lymphoma.

READ MORE

News

FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.

READ MORE

A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.

READ MORE

The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.

READ MORE

The US Food and Drug Administration (FDA) has made the first gene therapy available, marking their approval of a new approach to the treatment of cancer.

READ MORE

Resources

The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.

READ MORE